Using the multicenter dataset available within the Italian Neuroimaging Network Initiative, we compared the performance of different atrophy tools on brain MRI from 457 multiple sclerosis (MS) patients and 271 healthy controls, since monitoring neurodegeneration is one of the most important goals of therapeutic strategies in MS. We found an acceptable agreement and comparable performances among the software for GM and whole brain atrophy quantification. The free licence, speed and facility of integration in the clinical routine are also important aspects to consider for the selection of the atrophy pipeline. These results should be confirmed on large-scale longitudinal data.
This abstract and the presentation materials are available to members only; a login is required.